• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Zentalis Pharmaceuticals (ZNTL)

Common Shares
Sell: $1.38|Buy: $1.47|Change: 0.01 (-0.70%)

Open 

$1.44

Previous close 

$1.43

Trade high 

$1.535

Volume 

542,565

Year high 

$13.24

Year low 

$1.01

Dividend yield 

–

Market capitalisation 

$101.97 mn

P/E ratio 

–

ISIN 

US98943L1070

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Share price

Performance 28/04/2025

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

Total return (%)
Zentalis Pharmaceuticals- 0.70
More...

Company profile

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer(Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Sector 

Healthcare

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2025 AJ Bell. All rights reserved.